Table 1: Clinical, biochemical, and virological characteristics of the studied group.

Chronic liver disease ( = 41)NDC ( = 10)
HCCLCPCH

No (%)15/41 (36.6%)16/41 (39.0%)10/41 (24.4%)10/10 (100%)
Gender (M/F)13/212/49/17/3
Age (years) 57.06 ± 12.58 (60.0)46.06 ± 7.9 (45.0)35.8 ± 5.2 (37.5)35.6 ± 3.1 (35.5)
Albumin (g/dL)4.22 ± 0.58 (4.3)4.15 ± 0.467 (4.0)4.5 ± 0.42 (4.6)3.83 ± 0.29 (3.85)
T. protein (g/dL)7.95 ± 0.603 (8.0)7.6 ± 0.67 (7.8)7.66 ± 0.49 (7.85)7.22 ± 0.53 (7.15)
T. bilirubin (mg/dL)1.69 ± 2.57 (1.2)1.28 ± 1.54 (1.0)0.99 ± 0.54 (0.9)0.57 ± 0.21 (0.55)
AST (μ/mL)92.8 ± 65.67 (67.0)57.0 ± 26.6 (52.5)34.8 ± 11.44 (30.5)26.6 ± 5.5 (26.5)
ALT (μ/mL)58.73 ± 36.86 (46.0)49.0 ± 17.35 (49.0)32.6 ± 14.8 (25.5)27.7 ± 4.1 (27.5)
Proth. time (Sec)14.3 ± 1.7 (14.0)13.58 ± 4.66 (14.6)13.2 ± 4.77 (13.3)6.04 ± 0.568 (6.1)
Proth. conc. (%)72.26 ± 13.78 (70.0)70.375 ± 12.99 (69.0)73.1 ± 19.0 (78.0)258.4 ± 14.06 (256.0)

HCV infection
 Positive 11/15 (73.3%)14/16 (87.5%)8/10 (80%)0/10 (0.0%)
 Negative 4/15 (26.7%)2/16 (12.5%)2/10 (20%)10/10 (100%)

Tumor site
 Right lobe7/15 (46.7%)
 Left lobe8/15 (53.3%)

HCC grade
 Grade I2/15 (13.3%)
 Grade II4/15 (26.7%)
 Grade III9/15 (60.0%)

Child score
 A3/15 (20.0%)
 B6/15 (40.0%)
 C6/15 (40.0%)

Data expressed as mean ± SD (median).
Hepatocellular carcinoma (HCC), liver cirrhosis (LC), precirrhotic hepatitis (PCH), nondisease control (NDC).
Significant difference was detected between PCH and LC () and HCC ().
Significant difference was detected between PCH and LC () and HCC ().